Protalix BioTherapeutics
PLX
PLX
28 hedge funds and large institutions have $19.8M invested in Protalix BioTherapeutics in 2020 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
41% more capital invested
Capital invested by funds: $14.1M → $19.8M (+$5.71M)
24.21% less ownership
Funds ownership: 40.43% → 16.22% (-24%)
Holders
28
Holding in Top 10
–
Calls
$1.15M
Puts
$12K
Top Buyers
| 1 | +$2.55M | |
| 2 | +$681K | |
| 3 | +$615K | |
| 4 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$384K |
| 5 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$367K |
Top Sellers
| 1 | -$9.15M | |
| 2 | -$53K | |
| 3 | -$14K | |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$12K |
| 5 |
CA
Clearstead Advisors
Cleveland,
Ohio
|
-$1K |